Summary & Overview
HCPCS C9085: Injection, avalglucosidase alfa-ngpt, 4 mg
HCPCS Level II code C9085 denotes injection of avalglucosidase alfa-ngpt, 4 mg, a biologic enzyme replacement therapy administered by injection. Nationally, clear coding for high-cost specialty biologics is essential for consistent claims processing, clinical documentation, and payer coverage determinations. This code matters because it identifies a specific drug product and dosage unit that influences billing, reimbursement, and utilization management for specialty infusion services. Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find concise benchmarks and policy-relevant context for C9085, including an overview of reimbursement considerations for injectable biologics, common sites of service for administration, and typical clinical contexts where enzyme replacement therapy is used. The publication also summarizes payer coverage patterns and prior authorization trends for high-cost biologic injections. Data not available in the input is noted where applicable. This briefing provides actionable intelligence for coding staff, billing managers, and policy analysts responsible for specialty drug claims and site-of-service decisions.
Billing Code Overview
HCPCS Level II code C9085 represents Injection, avalglucosidase alfa-ngpt, 4 mg. This code describes a specific therapeutic biologic product administered by injection for enzyme replacement therapy. The service type is an injectable biologic medication administration, and the typical site of service is outpatient infusion or clinic administration settings such as hospital outpatient departments, ambulatory infusion centers, or specialty clinics.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient diagnosed with late-onset or infantile-onset Pompe disease receiving enzyme replacement therapy with avalglucosidase alfa-ngpt. The patient presents to an outpatient infusion center, hospital-based infusion suite, or specialty clinic for administration of C9085 (injection, avalglucosidase alfa-ngpt, 4 mg). The workflow includes verification of medication orders and dosing based on weight, pre-infusion assessment (vital signs, airway and respiratory status, infusion access check), review of premedication needs (antihistamines, corticosteroids if prior infusion reactions), establishing intravenous access, and programmed infusion pump setup. During infusion, nursing monitors for infusion-associated reactions (fever, rash, hypotension, bronchospasm) and documents vitals at regular intervals. Post-infusion observation occurs per institutional protocol (commonly 30–60 minutes) to ensure stability. Billing is submitted using the HCPCS Level II code C9085 with applicable modifiers for circumstances such as reduced services, services performed with a surgical team, or infusion-related unusual services. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and home infusion when clinically appropriate. The typical patient scenario includes ongoing, regularly scheduled infusions (for example, every two weeks) as part of chronic management, with episodic adjustments for dose changes, infusion reactions, or procedural interruptions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|